AU2012279043B2 - A system for extended storage of red blood cells and methods of use - Google Patents
A system for extended storage of red blood cells and methods of use Download PDFInfo
- Publication number
- AU2012279043B2 AU2012279043B2 AU2012279043A AU2012279043A AU2012279043B2 AU 2012279043 B2 AU2012279043 B2 AU 2012279043B2 AU 2012279043 A AU2012279043 A AU 2012279043A AU 2012279043 A AU2012279043 A AU 2012279043A AU 2012279043 B2 AU2012279043 B2 AU 2012279043B2
- Authority
- AU
- Australia
- Prior art keywords
- rbcs
- oxygen
- carbon dioxide
- reduced
- stored
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 495
- 238000003860 storage Methods 0.000 title claims abstract description 238
- 238000000034 method Methods 0.000 title claims abstract description 93
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 352
- 239000001301 oxygen Substances 0.000 claims abstract description 260
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 260
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 256
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 177
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 171
- 239000008280 blood Substances 0.000 claims description 148
- 210000004369 blood Anatomy 0.000 claims description 143
- 230000002829 reductive effect Effects 0.000 claims description 132
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 88
- 239000000654 additive Substances 0.000 claims description 53
- 239000000725 suspension Substances 0.000 claims description 53
- 230000000996 additive effect Effects 0.000 claims description 50
- 239000002594 sorbent Substances 0.000 claims description 41
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 claims description 40
- 239000000835 fiber Substances 0.000 claims description 25
- 210000000265 leukocyte Anatomy 0.000 claims description 24
- 244000052769 pathogen Species 0.000 claims description 18
- 239000012510 hollow fiber Substances 0.000 claims description 15
- 230000000779 depleting effect Effects 0.000 claims description 13
- 239000007789 gas Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 230000002503 metabolic effect Effects 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 239000013589 supplement Substances 0.000 claims description 8
- 239000004803 Di-2ethylhexylphthalate Substances 0.000 claims description 7
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 5
- 235000005875 quercetin Nutrition 0.000 claims description 5
- 229960001285 quercetin Drugs 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 3
- 108090000854 Oxidoreductases Proteins 0.000 claims description 3
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 3
- -1 alpha-tocopheral Chemical compound 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000002532 enzyme inhibitor Substances 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 239000002516 radical scavenger Substances 0.000 claims 2
- 235000003363 Cornus mas Nutrition 0.000 claims 1
- 240000006766 Cornus mas Species 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 8
- 238000004321 preservation Methods 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 43
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 37
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 34
- 230000008569 process Effects 0.000 description 24
- 108010054147 Hemoglobins Proteins 0.000 description 20
- 102000001554 Hemoglobins Human genes 0.000 description 20
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 17
- 230000002779 inactivation Effects 0.000 description 16
- 210000001772 blood platelet Anatomy 0.000 description 15
- 239000000306 component Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 230000001717 pathogenic effect Effects 0.000 description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 239000003642 reactive oxygen metabolite Substances 0.000 description 14
- 206010018910 Haemolysis Diseases 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 230000008588 hemolysis Effects 0.000 description 13
- 230000036961 partial effect Effects 0.000 description 13
- 230000006378 damage Effects 0.000 description 12
- 230000004888 barrier function Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 210000000601 blood cell Anatomy 0.000 description 9
- 230000001010 compromised effect Effects 0.000 description 9
- 239000004800 polyvinyl chloride Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229920000915 polyvinyl chloride Polymers 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 7
- 229930024421 Adenine Natural products 0.000 description 7
- 229960000643 adenine Drugs 0.000 description 7
- 230000002939 deleterious effect Effects 0.000 description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical class OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000021187 Transfusion associated graft versus host disease Diseases 0.000 description 6
- 239000008121 dextrose Substances 0.000 description 6
- 230000034659 glycolysis Effects 0.000 description 6
- 230000004792 oxidative damage Effects 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 238000006213 oxygenation reaction Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 238000005057 refrigeration Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 208000007056 sickle cell anemia Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- 238000004555 blood preservation Methods 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000254 damaging effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 229910000000 metal hydroxide Inorganic materials 0.000 description 3
- 150000004692 metal hydroxides Chemical class 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000003244 pro-oxidative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000003422 vasoregulatory effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000003846 Carbonic anhydrases Human genes 0.000 description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 description 2
- 206010013142 Disinhibition Diseases 0.000 description 2
- 206010065973 Iron Overload Diseases 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 108010064719 Oxyhemoglobins Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 239000012080 ambient air Substances 0.000 description 2
- ZRIUUUJAJJNDSS-UHFFFAOYSA-N ammonium phosphates Chemical class [NH4+].[NH4+].[NH4+].[O-]P([O-])([O-])=O ZRIUUUJAJJNDSS-UHFFFAOYSA-N 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006392 deoxygenation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000009340 pathogen transmission Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000004148 Annexin A4 Human genes 0.000 description 1
- 108090000669 Annexin A4 Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 244000122871 Caryocar villosum Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 206010071090 Transfusion related complication Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000006288 alpha thalassemia Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000002655 chelation therapy Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000006692 glycolytic flux Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- CCHNOBQMQBSRHQ-UHFFFAOYSA-N phosphoric acid;7h-purin-6-amine Chemical compound OP(O)(O)=O.NC1=NC=NC2=C1NC=N2 CCHNOBQMQBSRHQ-UHFFFAOYSA-N 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000003608 radiolysis reaction Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000001845 splenic macrophage Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
- A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0272—Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0429—Red blood cells; Erythrocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Dentistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504644P | 2011-07-05 | 2011-07-05 | |
| US201161504640P | 2011-07-05 | 2011-07-05 | |
| US61/504,640 | 2011-07-05 | ||
| US61/504,644 | 2011-07-05 | ||
| PCT/US2012/045426 WO2013006631A1 (en) | 2011-07-05 | 2012-07-03 | A system for extended storage of red blood cells and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012279043A1 AU2012279043A1 (en) | 2014-01-23 |
| AU2012279043B2 true AU2012279043B2 (en) | 2016-07-07 |
Family
ID=47437415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012279043A Active AU2012279043B2 (en) | 2011-07-05 | 2012-07-03 | A system for extended storage of red blood cells and methods of use |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP2729000B1 (https=) |
| JP (4) | JP2014518283A (https=) |
| CN (1) | CN103732056B (https=) |
| AU (1) | AU2012279043B2 (https=) |
| CA (1) | CA2840901C (https=) |
| ES (1) | ES2941907T3 (https=) |
| PT (1) | PT2729000T (https=) |
| WO (1) | WO2013006631A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12604890B2 (en) | 2015-03-10 | 2026-04-21 | Hemanext Inc. | Oxygen reduction disposable kits, devices and methods of use thereof |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12089589B2 (en) | 2009-10-12 | 2024-09-17 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| US11284616B2 (en) | 2010-05-05 | 2022-03-29 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| US9199016B2 (en) | 2009-10-12 | 2015-12-01 | New Health Sciences, Inc. | System for extended storage of red blood cells and methods of use |
| ES2959120T3 (es) | 2010-08-25 | 2024-02-20 | Hemanext Inc | Método para potenciar la calidad y la supervivencia de glóbulos rojos durante el almacenamiento |
| PT2635114T (pt) | 2010-11-05 | 2020-06-16 | New Health Sciences Inc | Irradiação de glóbulos vermelhos e armazenamento anaeróbico |
| US9067004B2 (en) | 2011-03-28 | 2015-06-30 | New Health Sciences, Inc. | Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly |
| AU2012279043B2 (en) * | 2011-07-05 | 2016-07-07 | Hemanext Inc. | A system for extended storage of red blood cells and methods of use |
| AU2012294269B2 (en) | 2011-08-10 | 2016-11-24 | Hemanext Inc. | Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device |
| EP2961269B1 (en) | 2013-02-28 | 2021-09-15 | Hemanext Inc. | Gas depletion device for blood products |
| WO2014183134A1 (en) * | 2013-05-10 | 2014-11-13 | President And Fellows Of Harvard College | Solutions for red blood cells |
| WO2015106240A1 (en) | 2014-01-13 | 2015-07-16 | The General Hospital Corporation | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin |
| US20160331783A1 (en) * | 2014-01-13 | 2016-11-17 | The General Hospital Corporation | Bisamide compounds as allosteric effectors for reducing the oxygen-binding affinity of hemoglobin |
| KR102554521B1 (ko) | 2014-02-20 | 2023-07-11 | 프레제니우스 카비 도이치란트 게엠베하 | 적혈구 제품, 혈장 및 혈소판의 보관을 위한 비-ｄｅｈｐ 가소제를 갖는 의료용 컨테이너 및 시스템 구성요소 |
| US20170105407A1 (en) * | 2014-05-21 | 2017-04-20 | Albert Einstein College Of Medicine, Inc. | Compositions and methods for enhancing red blood cell storage time and survivability using nitric oxide releasing hybrid hydrogel nanoparticles |
| CN104406831B (zh) * | 2014-11-21 | 2017-08-25 | 广东万事泰集团有限公司 | 血液分离装置、血液分离检测装置及分离检测方法 |
| KR20250126858A (ko) | 2015-04-23 | 2025-08-25 | 헤마넥스트 인코포레이티드 | 혐기성 혈액 저장 용기 |
| IL289099B2 (en) * | 2015-05-18 | 2024-04-01 | Hemanext Inc | Methods for the storage of whole blood, and compositions thereof |
| MX393877B (es) * | 2016-05-27 | 2025-03-24 | Hemanext Inc | Almacenamiento anaerobico de sangre y metodo de inactivacion de patogenos |
| IL305115A (en) * | 2016-06-23 | 2023-10-01 | Hemanext Inc | Methods for treating side effects in patient populations requiring transfusions |
| WO2017223318A1 (en) * | 2016-06-24 | 2017-12-28 | Dominique Uhlmann | System and Method for Continuous Flow Red Blood Cell Washing |
| CN106421949B (zh) * | 2016-08-29 | 2018-10-02 | 安徽通灵仿生科技有限公司 | 一种氧合引流管、氧合装置及氧合方法 |
| JP7837502B2 (ja) * | 2017-05-19 | 2026-03-31 | ヘマネクスト インコーポレイテッド | 外傷の方法および治療 |
| CN120189436A (zh) * | 2018-11-16 | 2025-06-24 | 希玛奈克斯特股份有限公司 | 用于控制炎症患者中不良事件的方法 |
| JPWO2023167248A1 (https=) * | 2022-03-01 | 2023-09-07 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011046841A1 (en) * | 2009-10-12 | 2011-04-21 | New Health Sciences, Inc. | Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities |
| WO2012027582A1 (en) * | 2010-08-25 | 2012-03-01 | New Health Sciences | Method for enhancing red blood cell quality and survival during storage |
| WO2012061731A1 (en) * | 2010-11-05 | 2012-05-10 | New Health Sciences | Irradiation of red blood cells and anaerobic storage |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6447987B1 (en) | 1978-09-09 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Prolonged storage of red blood cells |
| DE3582523D1 (de) | 1984-07-16 | 1991-05-23 | Sumitomo Bakelite Co | Behaelter und verfahren zur aufbewahrung von blut. |
| US4769318A (en) | 1986-06-03 | 1988-09-06 | Ube Industries, Ltd. | Additive solution for blood preservation and activation |
| US4880786A (en) | 1987-01-14 | 1989-11-14 | Ube Industries, Ltd. | Additive solution for blood preservation and activation |
| US4925572A (en) | 1987-10-20 | 1990-05-15 | Pall Corporation | Device and method for depletion of the leukocyte content of blood and blood components |
| US4880548A (en) | 1988-02-17 | 1989-11-14 | Pall Corporation | Device and method for separating leucocytes from platelet concentrate |
| US5152905A (en) | 1989-09-12 | 1992-10-06 | Pall Corporation | Method for processing blood for human transfusion |
| US5037419A (en) * | 1989-09-21 | 1991-08-06 | Eastman Kodak Company | Blood bag system containing vitamin E |
| ES2110002T3 (es) * | 1991-06-21 | 1998-02-01 | Baxter Int | Procedimiento de inactivacion de agentes patogenos en fluidos corporales. |
| US5443743A (en) | 1991-09-11 | 1995-08-22 | Pall Corporation | Gas plasma treated porous medium and method of separation using same |
| US5529821A (en) | 1992-06-29 | 1996-06-25 | Terumo Kabushiki Kaisha | Container for storing blood or blood component |
| US5476764A (en) | 1994-09-16 | 1995-12-19 | The Regents Of The University Of California | Method using CO for extending the useful shelf-life of refrigerated red blood cells |
| US5624794A (en) * | 1995-06-05 | 1997-04-29 | The Regents Of The University Of California | Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas |
| CA2258211C (en) | 1996-07-09 | 2003-05-13 | Pall Corporation | Multiple element filter |
| US6358678B1 (en) * | 1998-02-11 | 2002-03-19 | The United States Of America As Represented By The Secretary Of The Navy | Applications of reversible crosslinking and co-treatment in stabilization and viral inactivations of erythrocytes |
| US6482585B2 (en) * | 1997-04-16 | 2002-11-19 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Storage and maintenance of blood products including red blood cells and platelets |
| US6162396A (en) * | 1997-04-26 | 2000-12-19 | The Regents Of The University Of California | Blood storage device and method for oxygen removal |
| US5789151A (en) * | 1997-05-15 | 1998-08-04 | The Regents Of The University Of California | Prolonged cold storage of red blood cells by oxygen removal and additive usage |
| DE69912457T2 (de) * | 1998-08-31 | 2004-08-19 | Walter Reed Army Institute Of Research | Verlängerte lagerung roter blutzellen |
| US6413713B1 (en) | 1998-10-30 | 2002-07-02 | Hyperbaric Systems | Method for preserving blood platelets |
| US6945411B1 (en) | 1999-03-16 | 2005-09-20 | Pall Corporation | Biological fluid filter and system |
| US6548241B1 (en) * | 2000-11-28 | 2003-04-15 | Gambro, Inc. | Storage solution containing photosensitizer for inactivation of biological contaminants |
| WO2002096471A2 (en) * | 2001-05-30 | 2002-12-05 | Gambro, Inc. | Viral inactivation process using antioxidant |
| US20030124504A1 (en) * | 2001-11-16 | 2003-07-03 | Bitensky Mark W. | Additive solution for blood preservation |
| EP2208502B1 (en) * | 2001-12-10 | 2019-05-08 | Terumo BCT, Inc. | Disposable assembly for an apheresis system |
| US20040126880A1 (en) * | 2002-06-07 | 2004-07-01 | Manders Ernest K. | Sterilization, stabilization and preservation of functional biologics |
| US20080160107A1 (en) * | 2002-09-10 | 2008-07-03 | Nitric Biotherapeutics, Inc. | Use of nitric oxide gas to treat blood and blood products |
| US20080299538A1 (en) * | 2003-02-28 | 2008-12-04 | Caridianbct Biotechnologies, Llc | Pathogen Inactivation of Whole Blood |
| US7517453B2 (en) * | 2003-03-01 | 2009-04-14 | The Trustees Of Boston University | Microvascular network device |
| US7575856B2 (en) * | 2005-10-28 | 2009-08-18 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for the evaluation and resuscitation of cadaveric hearts for transplant |
| WO2008063868A2 (en) * | 2006-11-07 | 2008-05-29 | The General Hospital Corporation | Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
| AU2012279043B2 (en) * | 2011-07-05 | 2016-07-07 | Hemanext Inc. | A system for extended storage of red blood cells and methods of use |
-
2012
- 2012-07-03 AU AU2012279043A patent/AU2012279043B2/en active Active
- 2012-07-03 CA CA2840901A patent/CA2840901C/en active Active
- 2012-07-03 EP EP12807324.4A patent/EP2729000B1/en active Active
- 2012-07-03 CN CN201280038814.3A patent/CN103732056B/zh active Active
- 2012-07-03 WO PCT/US2012/045426 patent/WO2013006631A1/en not_active Ceased
- 2012-07-03 EP EP22212891.0A patent/EP4190154A1/en active Pending
- 2012-07-03 ES ES12807324T patent/ES2941907T3/es active Active
- 2012-07-03 JP JP2014519262A patent/JP2014518283A/ja active Pending
- 2012-07-03 PT PT128073244T patent/PT2729000T/pt unknown
-
2017
- 2017-03-21 JP JP2017054220A patent/JP2017122118A/ja active Pending
-
2018
- 2018-12-04 JP JP2018227269A patent/JP6857291B2/ja active Active
-
2020
- 2020-10-22 JP JP2020177109A patent/JP2021011497A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011046841A1 (en) * | 2009-10-12 | 2011-04-21 | New Health Sciences, Inc. | Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities |
| WO2012027582A1 (en) * | 2010-08-25 | 2012-03-01 | New Health Sciences | Method for enhancing red blood cell quality and survival during storage |
| WO2012061731A1 (en) * | 2010-11-05 | 2012-05-10 | New Health Sciences | Irradiation of red blood cells and anaerobic storage |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12604890B2 (en) | 2015-03-10 | 2026-04-21 | Hemanext Inc. | Oxygen reduction disposable kits, devices and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2729000A1 (en) | 2014-05-14 |
| ES2941907T3 (es) | 2023-05-26 |
| EP2729000B1 (en) | 2022-12-14 |
| EP4190154A1 (en) | 2023-06-07 |
| JP2019038852A (ja) | 2019-03-14 |
| JP6857291B2 (ja) | 2021-04-14 |
| CN103732056B (zh) | 2016-08-17 |
| WO2013006631A8 (en) | 2014-01-30 |
| CA2840901A1 (en) | 2013-01-10 |
| CA2840901C (en) | 2020-12-15 |
| EP2729000A4 (en) | 2014-12-03 |
| JP2014518283A (ja) | 2014-07-28 |
| PT2729000T (pt) | 2023-04-10 |
| WO2013006631A1 (en) | 2013-01-10 |
| JP2017122118A (ja) | 2017-07-13 |
| JP2021011497A (ja) | 2021-02-04 |
| CN103732056A (zh) | 2014-04-16 |
| AU2012279043A1 (en) | 2014-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12502462B2 (en) | System for extended storage of red blood cells and methods of use | |
| AU2012279043B2 (en) | A system for extended storage of red blood cells and methods of use | |
| JP7629891B2 (ja) | 嫌気性血液貯蔵および病原体不活性化方法 | |
| EP3539381B1 (en) | Irradiation of red blood cells and anaerobic storage | |
| CN114748503B (zh) | 储存全血的方法及其组合物 | |
| US11284616B2 (en) | Irradiation of red blood cells and anaerobic storage | |
| US12089589B2 (en) | Irradiation of red blood cells and anaerobic storage | |
| EP2777727B1 (en) | Methods and systems for processing biological fluids | |
| BR122025006831A2 (pt) | Método de redução de patógenos e formação de micropartícula reduzida no produto de sangue total | |
| BR122022007389B1 (pt) | Métodos de redução de patógenos do sangue, produto sanguíneos com oxigênio reduzido e hemácias isentas de patógenos com oxigênio reduzido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 61/504,644 05 JUL 2011 US AND 61/504,640 05 JUL 2011 US |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: HEMANEXT INC. Free format text: FORMER NAME(S): NEW HEALTH SCIENCES, INC. |